France: Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, has entered into a €15m US$17.03m) loan agreement with the European Investment Bank (EIB). The loan…
France: Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, has entered into a €15m US$17.03m) loan agreement with the European Investment Bank (EIB). The loan…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference


